Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

This Danish series, about a morning show in crisis, is light but not dumb, credible but still arch. It is also very different ...

CNBC’s Angelica Peebles reports on the latest news surrounding Eli Lilly.

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Sunrun (RUN), Plug Power (PLUG), and Array Technologies (ARRY) plunge after the Senate revealed its revisions to President ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, Lilly said on Tuesday.